Inflammatory Bowel Disease
The IBD Clinical Trials Team conducts clinical trials of new drugs for patients with inflammatory bowel diseases, including Crohn’s Disease, Ulcerative Colitis and related conditions.
ABTECT-1: A potential new treatment for UC
The ABTECT-1 Study is being done to learn more about an investigational medication, called Obefazimod or 'ABX464', and its effect in people with ulcerative colitis (UC). UC causes inflammation in the lining of the colon (large intestine). The main symptoms of UC are pain and recurring diarrhoea, which may contain blood and/or mucus.
Celgene - Do you have Eosinophilic Esophagitis and difficulty swallowing?
A multicentre study of the safety and effectiveness of CC-93538 in adolescent and adult participants with Eosinophilic Esophagitis
CROSSING - A new treatment for Eosinophilic Esophagitis
A study of the safety and effectiveness of tezepelumab in adolescent and adult participants with Eosinophilic Esophagitis
EMERALD2 - A new treatment for Ulcerative Colitis
A phase 2b study to evaluate MORF-057 in adults with moderately to severely active ulcerative colitis (UC).
ENGAGE
A study investigating the effectiveness & safety of Dupilumab in the treatment of eosinophilic gastritis with or without eosinophilic duodenitis.
FUZION - A potential treatment for Fistulizing, Perianal Crohn’s Disease
FUZION: Efficacy and safety of guselkumab in participants with fistulizing, perianal Crohn’s Disease
Palekona - An oral treatment for Ulcerative Colitis
Study of GS-5290 in participants with moderately to severely active ulcerative colitis
QUASAR Jr
The purpose of this study is to evaluate the effectiveness of guselkumab in pediatric participants with moderately to severely active ulcerative colitis through open label induction and through maintenance therapy among participants who were induction responders.
SWIFT - Do you have Moderate to Severely Active UC?
UPlift
A post-marketing study of UPadacitinib evaluating speed of onset and durability of effectiveness for patients with moderate to severe Crohn’s disease for 3 years in the real-world